These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
124 related items for PubMed ID: 8299527
41. Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats. Remuzzi A, Imberti O, Puntorieri S, Malanchini B, Macconi D, Magrini L, Bertani T, Remuzzi G. Am J Physiol; 1994 Dec; 267(6 Pt 2):F1034-44. PubMed ID: 7528985 [Abstract] [Full Text] [Related]
42. Renal effects of captopril, indomethacin and nifedipine in nephrotic patients after an oral protein load. Garini G, Mazzi A, Buzio C, Mutti A, Allegri L, Savazzi G, Borghetti A. Nephrol Dial Transplant; 1996 Apr; 11(4):628-34. PubMed ID: 8671850 [Abstract] [Full Text] [Related]
43. The effect of enalapril on proteinuria in patients with chronic glomerulonephritis and renal insufficiency. Yoshida A, Morozumi K, Takeda A, Koyama K, Ideura T, Ikeda M, Oikawa T. Nihon Jinzo Gakkai Shi; 1993 Nov; 35(11):1249-52. PubMed ID: 8139137 [Abstract] [Full Text] [Related]
44. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Praga M, Hernández E, Montoyo C, Andrés A, Ruilope LM, Rodicio JL. Am J Kidney Dis; 1992 Sep; 20(3):240-8. PubMed ID: 1519604 [Abstract] [Full Text] [Related]
45. Renal tubular peptide catabolism in chronic vascular rejection. Rustom R, Grime JS, Sells RA, Amara A, Jackson MJ, Shenkin A, Maltby P, Smith L, Hammad A, Brown M, Bone JM. Ren Fail; 2001 Sep; 23(3-4):517-31. PubMed ID: 11499566 [Abstract] [Full Text] [Related]
46. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Ruggenenti P, Mise N, Pisoni R, Arnoldi F, Pezzotta A, Perna A, Cattaneo D, Remuzzi G. Circulation; 2003 Feb 04; 107(4):586-92. PubMed ID: 12566371 [Abstract] [Full Text] [Related]
47. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ. Kidney Int; 2006 Apr 04; 69(8):1410-5. PubMed ID: 16541021 [Abstract] [Full Text] [Related]
48. Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure. Brooks DP, Short BG, Cyronak MJ, Contino LC, DiCristo M, Wang YX, Ruffolo RR. Br J Pharmacol; 1993 Jun 04; 109(2):581-6. PubMed ID: 8102931 [Abstract] [Full Text] [Related]
49. Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function. Bedogna V, Valvo E, Casagrande P, Braggio P, Fontanarosa C, Dal Santo F, Alberti D, Maschio G. Kidney Int; 1990 Jul 04; 38(1):101-7. PubMed ID: 2200924 [Abstract] [Full Text] [Related]
50. Captopril, an angiotensin I-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases. Ikeda T, Nakayama D, Gomi T, Sakurai J, Yamazaki T, Yuhara M. Nephron; 1989 Jul 04; 52(1):72-5. PubMed ID: 2651951 [Abstract] [Full Text] [Related]
51. Effects of angiotensin converting enzyme inhibitors on the progression of renal failure and proteinuria in humans. Rodicio JL, Praga M, Alcazar JM, Oliet A, Gutierrez-Millet V, Ruilope LM. J Hypertens Suppl; 1989 Sep 04; 7(7):S43-7. PubMed ID: 2693657 [Abstract] [Full Text] [Related]
52. In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progression. Cohen EP, Lemann J. Am J Kidney Dis; 1996 Feb 04; 27(2):199-203. PubMed ID: 8659493 [Abstract] [Full Text] [Related]
53. The role of paricalcitol on proteinuria. Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P. J Ren Care; 2011 Jun 04; 37(2):80-4. PubMed ID: 21561543 [Abstract] [Full Text] [Related]
54. Nephrotic-range proteinuria in patients with renovascular disease. Halimi JM, Ribstein J, Du Cailar G, Mimran A. Am J Med; 2000 Feb 04; 108(2):120-6. PubMed ID: 11126305 [Abstract] [Full Text] [Related]
55. MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis. Guasch A, Zayas CF, Badr KF. Kidney Int; 1999 Jul 04; 56(1):261-7. PubMed ID: 10411701 [Abstract] [Full Text] [Related]
56. Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M, Honda M, Yoshikawa N, Japanese Pediatric IgA Nephropathy Treatment Study Group. Pediatr Nephrol; 2009 Apr 04; 24(4):845-9. PubMed ID: 18825420 [Abstract] [Full Text] [Related]
57. The effects of lisinopril on renal function in proteinuric renal transplant recipients. Traindl O, Falger S, Reading S, Banyai M, Liebisch B, Gisinger J, Templ E, Mayer G, Kovarik J. Transplantation; 1993 Jun 04; 55(6):1309-13. PubMed ID: 8390733 [Abstract] [Full Text] [Related]
58. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Praga M, Borstein B, Andres A, Arenas J, Oliet A, Montoyo C, Ruilope LM, Rodicio JL. Am J Kidney Dis; 1991 Mar 04; 17(3):330-8. PubMed ID: 1996578 [Abstract] [Full Text] [Related]
59. Anti-proteinuric and anti-coagulatory effects of camostat mesilate in azotemic diabetics. Matsubara M, Taguma Y, Saito T, Yoshinaga K. Nihon Jinzo Gakkai Shi; 1992 Apr 04; 34(4):411-6. PubMed ID: 1635286 [Abstract] [Full Text] [Related]
60. Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment. Neubeck M, Fliser D, Pritsch M, Weisser K, Fliser M, Nussberger J, Ritz E, Mutschler E. Eur J Clin Pharmacol; 1994 Apr 04; 46(6):537-43. PubMed ID: 7995322 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]